05/10/2026
A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer
Seda Author(s) Paul Dickinson (Acknowledgement)
Date: 05/10/2026
Oct 2026
Seda’s Integrated Expertise Supports FDA Approval of Emcitate
Seda Author(s)
Date: Oct 2026
Published: Approval
May 2026
Physiologically Based Biopharmaceutics Modelling—Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report
Seda Author(s) H. Engman, P. A. Dickinson
Date: May 2026
Published: Pharmaceutics